尊龙凯时 - 人生就是搏!

On March 12th, the Saudi National Unified Procurement Company (NUPCO) officially announced the bidding results for the three-year centralized procurement project for outsourced testing services for public hospitals. Genalive, the joint venture of BGI Genomics, secured the tender with a contract value of 950 million RMB.

BGI Genomics worked closely with Saudi Arabia during the global pandemic. It delivered comprehensive nucleic acid testing solutions and virus sequencing platforms. This partnership helped establish variant monitoring capabilities, strengthening the country’s public health infrastructure and making a significant impact on epidemic prevention and control.

The collaboration marks the largest outsourced testing service contract secured by Genalive in Saudi Arabia to date, will provide strong support for enhancing local precision medicine services.

This tender is the largest in NUPCO's history in terms of value and the number of testing items. It covers multiple methodologies, including NGS, pathology, cytogenetics, and Sanger sequencing. It includes 930,000 testing services and will provide comprehensive solutions for 83 public hospitals across Saudi Arabia.

Genalive will offer services in whole genome sequencing (WGS), whole exome sequencing (WES), monogenic disease panel, non-invasive prenatal testing (NIPT), hereditary cancer screening, and preimplantation genetic testing (PGT).

As a joint venture between BGI Genomics and Saudi partner Tibbiyah Holding, Genalive integrates China’s cutting-edge genomics technology with Saudi Arabia’s healthcare resources, offering a full-spectrum service model spanning diagnostics, equipment supply, and technical training.

This collaboration highlights Saudi Arabia's recognition of BGI Genomics' expertise and strengthens China-Saudi ties in precision medicine. Supporting Saudi Vision 2030, BGI Genomics will integrate AI with genetic technology to enhance disease prevention, early screening, and personalized healthcare in the region.

BGI Genomics

BGI Genomics, headquartered in Shenzhen, China, is the world's leading integrated solutions provider of precision medicine. Our services cover more than 100 countries and regions, involving more than 2,300 medical institutions. In July 2017, as a subsidiary of BGI Group, BGI Genomics (300676.SZ) was officially listed on the Shenzhen Stock Exchange.

Read more

BGI Genomics Hosts Saudi Delegation for Strategic Collaboration at BGI Center

Pioneering Precision Medicine in Saudi Arabia Through Innovation